Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform.
Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 9, 2022 | Series A | — | 7 |
|
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
|
Yes | Series A |
|
— | Series A |
|
— | Series A |
![]() |
— | Series A |
|
— | Series A |
![]() |
— | Series A |
|
— | Series A |